Accelerate Diagnostics Inc. (NASDAQ:AXDX) shares fell 3.7% during mid-day trading on Friday . The company traded as low as $22.15 and last traded at $22.17, with a volume of 173,902 shares traded. The stock had previously closed at $23.02.

A number of brokerages have recently issued reports on AXDX. Piper Jaffray Cos. restated an “overweight” rating and issued a $25.00 price target on shares of Accelerate Diagnostics in a research report on Monday, May 16th. BTIG Research restated a “buy” rating and issued a $26.00 price target on shares of Accelerate Diagnostics in a research report on Tuesday, August 9th. JPMorgan Chase & Co. boosted their price target on shares of Accelerate Diagnostics from $17.00 to $25.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 9th. Finally, Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $25.33.

The firm’s 50 day moving average is $19.64 and its 200-day moving average is $14.73. The company’s market capitalization is $1.16 billion.

In other Accelerate Diagnostics news, Director Jack W. Schuler purchased 14,033 shares of Accelerate Diagnostics stock in a transaction on Tuesday, June 14th. The shares were acquired at an average cost of $13.67 per share, for a total transaction of $191,831.11. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jack W. Schuler purchased 88,316 shares of Accelerate Diagnostics stock in a transaction on Friday, June 10th. The shares were acquired at an average price of $14.69 per share, for a total transaction of $1,297,362.04. The disclosure for this purchase can be found here.

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.